Introduction
Clostridium difficile is the primary cause of nosocomial antibiotic-associated diarrhea, with clinical symptoms ranging from mild diarrhea to pseudomembranous colitis or toxic megacolon, with a mortality rate of up to 25%-40%. 1 An epidemic C. difficile strain circulating in western countries had been assigned to the North American pulse-field type 1 (NAP1), restriction endonuclease analysis group BI, and polymerase 
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Hung et al chain reaction (PCR) ribotype 027 (sometimes referred to as BI/NAP1/027) has 3 important microbiological characters: increased production of toxin A and B (in conjunction with tcdC deletion), fluoroquinolone resistance, and production of binary toxin (encoded by cdtA and cdtB). 2 Toxigenic C. difficile isolates with tcdC deletion, cdtA, and cdtB have been found in Taiwan. [3] [4] [5] [6] [7] Three cluster cases presenting infectious diarrhea with multiple recurrences due to C. difficile RT126, belonging to RT078 lineage, were reported in 2014. 3 In the following year, 3 cases infected by RT027 were reported in Taiwan, with clinical manifestations of pseudomembranous colitis, toxic megacolon or bowel perforation. [4] [5] [6] In addition to the RT027 and RT078 lineage isolates, toxigenic C. difficile isolates harboring tcdB and truncated tcdA were predominant, accounting for 43.3% of infections in a district hospital in Taiwan. 7 C. difficile RT027 and RT078 isolates were reported sporadically in Mainland China. 8 Information about the toxin genes or ribotype distribution of toxigenic or hypervirulent C. difficile isolates in Taiwan has not been reported.
Some metronidazole-or vancomycin-resistant C. difficile isolates were observed in Taiwan. Among 403 non-duplicate isolates of C. difficile from 3 teaching hospitals in Taiwan between 2005 and 2010, all isolates were susceptible to metronidazole, but 2 had reduced susceptibility to vancomycin (minimum inhibitory concentration [MIC], 4 mg/L). 9 In a retrospective study in a medical center in northern Taiwan, 2 (1.8%) isolates in 2003 showed resistance to metronidazole (MIC >32 mg/L) and 5 (4.5%) obtained in 2003 (n=1), 2006 (n=1), and 2007 (n=3) showed resistance to vancomycin (MIC >2 mg/L). 10 Doxycycline and tigecycline had been suggested as potential alternatives for C. difficile infection (CDI). 9, 11 Tigecycline was in vitro highly active against an earlier collection, between 2001 and 2009, of clinical C. difficile isolates in Taiwan. 12 In the present study, we conducted a multicenter and prospective study to investigate the distribution of toxin genes, ribotypes, and antimicrobial susceptibilities among clinical C. difficile isolates from 2015 to 2016 in Taiwan.
Patients and methods

Hospital settings
This study was conducted in the National Taiwan University Hospital (Hospital A: a medical center in northern Taiwan), Chung Shan Medical University Hospital (B: a medical center in central Taiwan), Chi-Mei Hospital (C: a medical center in southern Taiwan), National Cheng Kung University Hospital (D: a medical center in southern Taiwan), and Tainan Hospital, Ministry of Health and Welfare (E: a district hospital in southern Taiwan), as noted in Figure 1 .
C. difficile isolates collected from participating hospitals
This study was conducted from January 2015 to December 2016, and only patients aged at least 20 years were included. In routine clinical care, stool samples from those with suspected CDI were tested by GeneXpert C. difficile PCR assay (Cepheid, CA, USA) in the Hospital A, BD GeneOhm™ Cdiff PCR assay (BD Diagnostics, San Diego, CA, USA) in the Hospital B, C, and D, or C. Diff Quik Chek Complete (Alere, Waltham, MA, USA) in the Hospital E. If positive, stools were plated on cycloserine-cefoxitin-fructose agar and incubated anaerobically for 24-48 h. During the study period, fecal samples or C. difficile isolates in the Hospital A, B, C, and E, were submitted to the Hospital D for cultures and further tests. For surveillance purposes, the isolate collected >60 days after the initial one was considered a new and distinct one and those collected between 14 and 60 days after the initial isolate were regarded as recurrent ones. 13 The isolates obtained within 14 days after the initial isolate were excluded.
Multiplex PCRs for toxin genes and PCR ribotyping
C. difficile isolates were sub-cultured on cycloserine-cefoxitin fructose selective plates and incubated anaerobically for 24-48 h. The colony with suspected morphology of C. difficile from the culture plate was selected for further identification and studies. A multiplex PCR detecting 16S ribosomal RNA, tpi (encoding triose phosphate isomerase, used as a C. difficile-specific marker), tcdA (encoding toxin A), tcdB (encoding toxin B), cdtA and cdtB (encoding binary toxin), and tcdC deletion, and PCR ribotyping were performed at the Hospital D, as previously described.
14 Briefly, after PCR amplification, the samples were concentrated using the Gel/ PCR DNA Fragments Extraction Kit (Geneaid Biotech, New Taipei, Taiwan) and separated with the QIAxcel capillary electrophoresis system (Qiagen, Hilden, Germany) using the "OM500" method and QX Alignment Marker 15 bp/3 kb (Qiagen, Hilden, Germany). The PCR ribotypes were confirmed by the WEBRIBO database (http://webribo.ages.at). 
Antimicrobial susceptibility testing
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Clostridium difficile in Taiwan Institute (CLSI) guidelines (M11-A8). 15 Supplemented Brucella agar deeps were obtained from Anaerobe Systems (Morgan Hill, CA, USA). Frozen defibrinated sheep blood (Hema Resources Inc., Aurora, OR, USA) was thawed to produce laked blood. On the day of testing, laked blood and antimicrobial agents were added to tubes of molten agar before pouring into agar dilution plates. The tested isolates were applied to the plates using a Steers multipronged inoculator for a final concentration of ~10 5 colony forming unit/spot. After 44 h of incubation at 36°C in an anaerobic chamber incubator, the plates were examined for bacterial growth and the MICs interpreted. Metronidazole and vancomycin were tested at concentrations of 0.03 to 512 mg/L, and MIC breakpoints for resistance are defined as ≥32 and ≥16 mg/L, respectively, according to CLSI 2012. 15 Quality control strains included Bacteroides fragilis ATCC 25285, C. difficile ATCC 700057, Staphylococcus aureus ATCC 29213, and Enterococcus faecalis ATCC 29212. The MIC was defined as the lowest concentration that yielded no visible growth or a marked change/reduction in growth compared to the growth controls. MIC breakpoints for resistance to doxycycline and tigecycline are defined as ≥8 and ≥0.5 mg/L, respectively, according to a previous report 11 and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) version 6.0. 16 
Statistical analysis
Statistical analysis was performed using the statistical software, SPSS, version 13.0. The c 2 -test or Fisher's test was used for categorical variables, and a 2-tailed P-value of <0.05 was considered statistically significant. 
Ethical approval
Results
Laboratory burden of C. difficile tests in study hospitals
In the 2-year period, the incidence of C. difficile tests performed in 5 hospitals varied greatly, ranging from 53.3 to 284.6 tests per 100,000 patient-days in 2015 and 43.2-312.9 tests per 100,000 patients-days in 2016. With a positivity rate of 10.6%-23.6% in 2015 and 6.0%-22.1% in 2016, the incidence of positive C. difficile tests ranged from 7.3 to 48.3 tests per 100,000 patient-days in 2015 and 5.8 to 63.0 tests per 100,000 patient-days in 2016 (Figure 1) . 
Ribotypes of C. difficile isolates
difficile isolates in Taiwan
Metronidazole MICs of the 1112 C. difficile isolates ranged from <0.125 to >32 mg/L, and metronidazole resistance rate varied among hospitals, ranging from 0.6% (Hospital E) to 3.3% (Hospital C). Vancomycin MICs ranged from <0.0625 to >8 mg/L, and vancomycin resistance rate ranged from 1.1% (Hospital B) to 4.6% (Hospital C) ( Table 2) . As for tigecycline, MIC values ranged from ≤0.0625 to >32 mg/L, and resistance to tigecycline (arbitrarily defined as MIC ≥0.5 mg/L) was noted in 0.6%-3.2% of the isolates in 5 hospitals. In contrast, the MIC range of doxycycline was between ≤0.0625 and >32 mg/L, and doxycycline resistance (defined as doxycycline MIC ≥8 mg/L) was present in 7.7%-17.3% of the isolates from different hospitals (Table 3) . However, doxycycline and tigecycline MICs of <0.0625 mg/L were noted in 51.4% and 92.3%, respectively, of all C. difficile isolates.
Overall, 1.2%, 2.1%, and 1.9% of toxigenic C. difficile isolates were resistant to metronidazole, vancomycin, and tigecycline, respectively, and the corresponding figure for non-toxigenic isolates was 1.5%, 1.1%, and 2.2%, respectively (Table 4) . However, doxycycline resistance was observed in 10.7% and 10.7% of toxigenic and non-toxigenic isolates, respectively.
Compared with toxigenic isolates of non-RT078 lineage, more toxigenic RT078 lineage isolates exhibited reduced susceptibility to doxycycline (MIC >8 mg/L: 75.9%, 44/58% vs 6.0%, 47/784; P<0.001) and tigecycline (MIC >0.125 mg/L: 20.7%, 12/58 vs 6.5%, 51/784; P<0.001). Note: *Resistance is defined as the breakpoints in Clinical and Laboratory Standards Institute Guidelines.
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Abbreviations: MIC50, minimum inhibitory concentration required to inhibit 50% of bacteria; MIC90, minimum inhibitory concentration required to inhibit 90% of bacteria. Note: *MIC breakpoints for resistance to doxycycline and tigecycline are defined as ≥8 and ≥0.5 mg/L, respectively.
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Abbreviations: MIC50, minimum inhibitory concentration required to inhibit 50% of bacteria; MIC90, minimum inhibitory concentration required to inhibit 90% of bacteria. 18 respectively, and 42.4/100,000 patient-day in a prospective study in Hospital E. 19 However, the present study reported the laboratory burden of C. difficile tests, either PCR or enzyme immunoassay, ranging from 43.2 to 312.8 tests/100,000 patient-days, which may be related to the real burden of CDIs or the clinical awareness of CDIs among attending physicians. The incidence of positive C. difficile tests ranged from 5.8 to 63.0 tests/100,000 patient-day and the positive test rate ranged from 6.0% to 23.6% among study hospitals. These data suggest the substantial, although geographically diverse, disease burden of CDIs in Taiwan.
In our study, although the distribution of the toxin gene pattern, ribotype or antimicrobial susceptibility varied in each hospital, the dominant ribotypes among C. difficile isolates with tcdC deletion, cdtA, and cdtB from 5 hospitals in 3 major cities in Taiwan were RT078 and RT027 lineages. C. difficile RT078 lineage isolates (such as RT126 and 127) have been linked to animal reserves or contact 20 and zoonotic potential of RT078 lineage in Taiwan warrants more investigations. The emergence of severe colitis due to C. difficile RT027 and RT078 in Taiwan and Asia indicates the need for comprehensive surveillance of CDI and molecular typing of clinical C. difficile isolates in the continent with a significant burden of multidrug-resistant organisms.
Metronidazole and vancomycin are regarded as the primary therapy options for CDI, depending on the severity of disease.
2 Among a collection of >800 clinical toxigenic C. difficile isolates in our study, 1.2% or 2.1% were resistant to metronidazole or vancomycin, respectively. The published literature also indicates that antimicrobial resistance to 2 commonly prescribed antimicrobial agents was rare among clinical C. difficile isolates from several southeastern and northeastern Asian countries.
Lower MICs were noted for doxycycline and tigecycline, which were suggested as alternative choices for CDI. 9, 11 In a study for each day of doxycycline receipt, the CDI rate was 27% lower than that of no doxycycline therapy (hazard ratio, 0.73; 95% CI: 0.56-0.96). 21 Successful treatment with CDI using tigecycline-based combination regimens was reported. 22 A previous study reported that in clinical isolates in Taiwan, the in vitro susceptibility rate of C. difficile to tigecycline was high. 12 Both doxycycline and tigecycline revealed relatively low MICs among C. difficile isolates, except in some RT078 lineage isolates in the study. Resistance to one or more of drugs tetracycline, moxifloxacin, clindamycin, or erythromycin has been reported in 26.9% (46) of 171 C. difficile isolates in Australia, predominantly RT126 and 078. 23 The clinical utility of doxycycline or tigecycline alone or in combination as therapeutic alternatives for CDI warrants further investigations.
Limitations
There were some limitations in our study. First, because the protocols or clinical algorithms to harvest C. difficile isolates from stool samples varied, we cannot compare the CDI incidence among study hospitals. Second, clinical information was not available to be correlated with the distribution of toxin genes, ribotypes, and antimicrobial susceptibilities. The clinical implications of predominant ribotypes among C. difficile isolates with tcdC deletion, cdtA, and cdtB or antimicrobial resistance in Taiwan warrant further studies. Third, the ribotypes of more than 700 tcdA+/tcdB+/cdtA−/ cdtB− C. difficile isolates were not investigated, and the likelihood of the existence of other predominant ribotypes in Taiwan cannot be excluded. Finally, no local information of antibiotic consumption in pig feed was available, so the potential linkage between higher prevalence of reduced susceptibility to doxycycline and tigecycline in RT078 isolates and agricultural antibiotic use remains obscure.
Conclusion
The dominant ribotypes among C. difficile isolates with tcdC deletion, cdtA, and cdtB were RT078 and RT027 lineages. Metronidazole or vancomycin resistance remained rare in toxigenic C. difficile isolates, but reduced susceptibility to doxycycline and tigecycline was more common among RT078 than non-RT078 lineage isolates.
